Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | COO | January 06, 2026 | January 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 547,408 |
Last balance in matching sequence
After 2026-01-06 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-01-06 · Gift · Disposed 540 · Balance 474,368 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2026-01-06 · Gift · Disposed 540 · Balance 473,828 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 3 · 2026-01-06 · Gift · Disposed 540 · Balance 473,288 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 4 · 2026-01-06 · Gift · Disposed 440 · Balance 472,848 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 5 · 2026-01-06 · Gift · Disposed 440 · Balance 472,408 F1: Gift to relatives F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 6 · 2026-01-06 · Grant · Acquired 75,000 · Balance 547,408 F3: Represents shares underlying restricted stock units which will vest in four equal annual installments. F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Gift to relatives
F2: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F3: Represents shares underlying restricted stock units which will vest in four equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 547,408 F3 · shares: Represents shares underlying restricted stock units which will vest in four equal annual installments. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,408 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 440 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,848 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,288 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,828 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 23:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,368 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 46 | $68.00 | $3,128.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 17 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,908 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,336 | $64.04 | $149,597.44 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 16 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,954 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F14 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,873 | $62.91 | $369,470.43 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 15 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,290 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F13 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 900 | $62.25 | $56,025.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 14 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 483,163 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F12 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 600 | $61.12 | $36,672.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 13 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,063 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F11 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 313 | $68.00 | $21,284.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 12 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,663 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 900 | $66.01 | $59,409.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 11 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,976 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F10 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,700 | $64.44 | $173,988.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 10 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 485,876 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F9 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 11,842 | $63.84 | $755,993.28 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 9 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 488,576 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F8 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 13,451 | $62.96 | $846,874.96 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 8 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 500,418 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,164 | $62.23 | $383,585.72 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 7 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 513,869 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 4,368 | $61.20 | $267,321.60 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 520,033 F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · shares: Partial disposition of shares to satisfy tax withholding obligations. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 524,401 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 524,961 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 525,521 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 526,081 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 31, 2025 Filed Jan 6, 2026 02:50 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GiftCommon Stock | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 526,641 F1 · kind: Gift to relatives F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| January 07, 2025 Filed Jan 8, 2025 02:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,000 | $19.69 | $157,520.00 |
DisclosureSEC source: 0001628280-25-000806 · wk-form4_1736303281.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,201 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 19.64 to $19.78, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 02:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 9,526 | $20.10 | $191,472.60 |
DisclosureSEC source: 0001628280-25-000806 · wk-form4_1736303281.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 535,201 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $ 20.01 to $ 20.21, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 02:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 19,658 | $19.69 | $387,066.02 |
DisclosureSEC source: 0001628280-25-000806 · wk-form4_1736303281.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 544,727 F2 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 to $20.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F5 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2025 Filed Jan 8, 2025 02:28 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-000806 · wk-form4_1736303281.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 564,385 F1 · shares: Represents shares underlying restricted stock units with a grant date 01/04/2025, which will vest in four equal annual installments. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 12,741 | $35.65 | $454,216.65 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 9 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 464,385 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.49 to $35.96, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,200 | $34.99 | $286,918.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 8 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 477,126 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.465 to $35.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,900 | $33.99 | $64,581.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 7 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 485,326 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.45 to $34.45, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 487,226 F7 · shares: Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments. Read SEC document |
| January 04, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,600 | $32.63 | $52,208.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 402,226 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,700 | $32.65 | $55,505.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,826 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 400 | $33.41 | $13,364.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,526 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.76, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,800 | $32.52 | $91,056.00 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 405,926 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.22 to $32.91, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,849 | $31.83 | $122,513.67 |
DisclosureSEC source: 0001628280-24-000744 · wk-form4_1704502718.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,726 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.21 to $32.19, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 00:30 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 7,500 | $37.39 | $280,425.00 |
DisclosureSEC source: 0001209191-23-002481 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,375 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.73, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 00:30 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 7,500 | $37.39 | $280,425.00 |
DisclosureSEC source: 0001209191-23-002481 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,875 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.73, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 9 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,375 F9 · shares: Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23. F10 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 270 | $40.53 | $10,943.10 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 8 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,375 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F8 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.42 to $40.80, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 300 | $39.55 | $11,865.00 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 7 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,645 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F7 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.30 to $39.72, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,286 | $38.58 | $203,933.88 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 6 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,945 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F6 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.10 to $39.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,894 | $37.58 | $108,756.52 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,231 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F5 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.06 to $38.05, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 70 | $40.80 | $2,856.00 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 4 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,125 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 500 | $39.74 | $19,870.00 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 3 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,195 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F4 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.47 to $40.28, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,527 | $38.54 | $213,010.58 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 2 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,695 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.03 to $38.89, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 00:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,653 | $37.53 | $99,567.09 |
DisclosureSEC source: 0001209191-23-002114 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · COO and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,222 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.03 to $38.02, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 01:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 32,000 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-22-062530 · doc4.xml · derivative · entry 2 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,000 shares Expires 2026-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents the first vesting date. Option vested over four years from date of grant. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 01:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 32,000 | $6.15 | $196,800.00 |
DisclosureSEC source: 0001209191-22-062530 · doc4.xml · nonDerivative · entry 1 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the reporting person which are subject to certain vesting conditions. Read SEC document |
| January 05, 2022 Filed Jan 8, 2022 01:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 316 | $64.35 | $20,334.60 |
DisclosureSEC source: 0001209191-22-002599 · doc4.xml · nonDerivative · entry 5 O'Brien Patrick · CIK 0001627183 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,875 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.